Data di Pubblicazione:
2005
Citazione:
Muraglitazar Bristol-Myers Squibb/Merck / D. Barlocco. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - 6:4(2005), pp. 427-434.
Abstract:
A review. Bristol-Myers Squibb and Merck & Co are co-developing muraglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma agonist, for the potential treatment of type 2 diabetes and other metabolic disorders. In Nov. 2004, approval was anticipated as early as mid-2005.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
D. Barlocco
Link alla scheda completa:
Link al Full Text: